Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Boston, Massachusetts 02130


Purpose:

This 1-year study will compare the safety, effectiveness and tolerability of clozapine and risperidone (Risperdal®) in patients with first episode schizophrenia and cannabis use disorder.


Study summary:

Early drug intervention may improve the long-term course of schizophrenia. While clinicians routinely use novel antipsychotics in treating first episode schizophrenia, the novel drug clozapine (CLOZ) is not used clinically because of its side effects and the difficulties associated with its use. CLOZ, however, may be relatively safe and particularly helpful for first episode patients who are comorbid for cannabis use disorder. Participants in this study are randomly assigned to recieve either CLOZ or risperidone weekly for 1 year. Global functioning, quality of life, and neurocognitive functioning are assessed throughout the study and post-treatment. Clinical rating scales, self report questionnaires, neuropsychological tests, and physical exams are used to assess participants.


Criteria:

Inclusion Criteria: - First episode of schizophrenia and a recent history of cannabis use - Treatment with an antipsychotic drug at study entry Exclusion Criteria: - Medical contraindications to treatment with clozapine or risperidone - History of seizure disorder or blood dyscrasia - Pregnancy - History of substance use disorder with evidence of recent use - Antipsychotic drug use > 12 weeks - History of psychosis > 2 years


NCT ID:

NCT00063349


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02130
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 11, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.